MAPT and Alzheimer disease: As shown in Figure 5b,c, the developed T807/RPCNP-CUR could target p-Tau and inhibit the expression of p-Tau in HT22 cells to almost normal levels, indicating that the nanoplatform could be used for targeted degradation of p-Tau to relieve AD symptoms.